Coloplast''s full-year revenue grew and EPS declined slightly. See why the stock is still a bit overvalued and not a good investment currently.
Coloplast A/S (OTCPK:CLPBF) Q4 2022 Earnings Conference Call November 07, 2022 09:00 AM ET Company Participants Kristian Villumsen - President & Chief Executive Officer Anders…
Coloplast ASB press release (CLPBF): Q4 GAAP EPS of $22.11.Revenue of $6.05B (+20.8% Y/Y) beats by $3.04B.
The following slide deck was published by Coloplast A/S in conjunction with their 2022 Q4 earnings call.
Coloplast is introducing the Saffron Fixation System designed for ease and reliability during pelvic floor reconstruction for women who suffer from pelvic organ prolapse (POP). “Our goal was to create an easy-to-use fixation tool that enables physicians to consistently attach sutures to the ligaments of the pelvic floor. We want to invest in products that help surgeons treat women suffering